To include your compound in the COVID-19 Resource Center, submit it here.

Myriad Pharmaceuticals cancer news

Myriad restructured and reduced headcount by 21 (13%) to about 140 to focus on its cancer pipeline. The company's lead cancer compound is

Read the full 235 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE